Top

Published in:

01-12-2008 | Review

Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer’s and Parkinson’s disease brains

Authors: Valerie Askanas, W. King Engel

Published in: Acta Neuropathologica | Issue 6/2008

Abstract

Sporadic inclusion-body myositis (s-IBM), the most common muscle disease of older persons, is of unknown cause and lacks successful treatment. Here we summarize diagnostic criteria and discuss our current understanding of the steps in the pathogenic cascade. While it is agreed that both degeneration and mononuclear-cell inflammation are components of the s-IBM pathology, how each relates to the pathogenesis remains unsettled. We suggest that the intra-muscle-fiber degenerative component plays the primary role, leading to muscle-fiber destruction and clinical weakness, since anti-inflammatory treatments are not of sustained benefit. We discuss possible treatment strategies aimed toward ameliorating a degenerative component, for example, lithium and resveratrol. Also discussed are the intriguing phenotypic similarities between s-IBM muscle fibers and the brains of Alzheimer and Parkinson’s diseases, the most common neurodegenerative diseases associated with aging. Similarities include, in the respective tissues, cellular aging, mitochondrial abnormalities, oxidative and endoplasmic-reticulum stresses, proteasome inhibition and multiprotein aggregates.

Abou-Sleiman PM, Muqit MMK, Wood NW (2006) Expanding insights of mitochondrial dysfunction in Parkinson’s disease. Nat Rev Neurosci 7:207–219. doi:10.1038/nrn1868 PubMed

Askanas V, Alvarez RB, Engel WK (1993) β-Amyloid precursor epitopes in muscle fibers of inclusion body myositis. Ann Neurol 34:551–560. doi:10.1002/ana.410340408 PubMed

Askanas V, Alvarez RB, Mirabella M, Engel WK (1996) Use of antineurofilament antibody to identify paired-helical filaments in inclusion-body myositis. Ann Neurol 39:389–391. doi:10.1002/ana.410390318 PubMed

Askanas V, Engel WK, Alvarez RB, McFerrin J, Broccolini A (2000) Novel immunolocalization of α-synuclein in human muscle of inclusion-body myositis, regenerating and necrotic muscle fibers, and at neuromuscular junctions. J Neuropathol Exp Neurol 59:592–598PubMed

Askanas V, Engel WK, Alvarez RB (1992) Light- and electronmicroscopic localization of β-amyloid protein in muscle biopsies of patients with inclusion-body myositis. Am J Pathol 141:31–36PubMed

Askanas V, Engel WK, Alvarez RB (1993) Enhanced detection of Congo-red positive amyloid deposits in muscle fibers of inclusion-body myositis and brain of Alzheimer’s disease using fluorescence technique. Neurology 43:1265–1267PubMed

Askanas V, Engel WK, Bilak M, Alvarez RB, Selkoe DJ (1994) Twisted tubulofilaments of inclusion-body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau. Am J Pathol 144:177–187PubMed

Askanas V, Engel WK, Yang C-C, Lee M-Y, Wisniewski G (1998) Light and electron microscopic immunolocation of Presenilin 1 in abnormal muscle fibers of patients with sporadic inclusion-body myositis and autosomal-recessive inclusion-body myopathy. Am J Pathol 152:889–895PubMed

Askanas V, Engel WK (1998) Does overexpression of BetaAPP in aging muscle have a pathogenic role and a relevance to Alzheimer’s disease. Am J Pathol 153:1673–1677PubMed

10.

Askanas V, Engel WK (2001) Inclusion-body myositis: newest concepts of pathogenesis and relation to aging and Alzheimer disease. J Neuropathol Exp Neurol 60:1–14PubMed

11.

Askanas V, Engel WK (2003) Proposed pathogenetic cascade of inclusion-body myositis: importance of amyloid-β misfolded proteins, predisposing genes, and aging. Curr Opin Rheumatol 15:737–744. doi:10.1097/00002281-200311000-00009 PubMed

12.

Askanas V, Engel WK (2006) Inclusion-body myositis: a myodegenerative conformational disorder associated with Aβ, protein-misfolding, and proteasome inhibition. Neurology 66:S39–S48. doi:10.1212/01.wnl.0000192128.13875.1e PubMed

13.

Askanas V, Engel WK (2007) Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis. Curr Opin Rheumatol 19:550–559. doi:10.1097/BOR.0b013e3282efdc7c PubMed

14.

Askanas V, McFerrin J, Alvarez RB, Baque S, Engel WK (1997) βAPP gene transfer into cultured human muscle induces inclusion-body myositis aspects. Neuroreport 8:2155–2158. doi:10.1097/00001756-199707070-00012 PubMed

15.

Askanas V, McFerrin J, Baque S, Alvarez RB, Sarkozi E, Engel WK (1996) Transfer of beta-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. Proc Natl Acad Sci USA 93:1314–1319. doi:10.1073/pnas.93.3.1314 PubMed

16.

Askanas V, Serdaroglu P, Engel WK, Alvarez RB (1992) Immunocytochemical localization of ubiquitin in inclusion body myositis allows its light-microscopic distinction from polymyositis. Neurology 42:460–461PubMed

17.

Baron P, Galimberti D, Meda L, Scarpini E, Conti G, Cogiamanian F et al (2001) Production of IL-6 by human myoblasts stimulated with Abeta: relevance in the pathogenesis of IBM. Neurology 57:1561–1565PubMed

18.

Blachere NE, Li Z, Chandawarkar RY, Suto R, Jaikaria NS, Basu S et al (1997) Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med 186:1315–1322. doi:10.1084/jem.186.8.1315 PubMed

19.

Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E et al (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299:256–259. doi:10.1126/science.1077209 PubMed

20.

Bossy-Wetzel E, Schwarzenbacher R, Lipton SA (2004) Molecular pathways to neurodegeneration. Nat Med 10:S2–S9. doi:10.1038/nm1067 PubMed

21.

Brunn A, Schröder R, Deckert M (2006) The inflammatory reaction pattern distinguishes primary dysferlinopathies from idiopathic inflammatory myopathies: an important role for the membrane attack complex. Acta Neuropathol 112:325–332. doi:10.1007/s00401-006-0113-5 PubMed

22.

Chahin N, Engel AG (2008) Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 70:418–424. doi:10.1212/01.wnl.0000277527.69388.fe PubMed

23.

Chang KA, Kim HS, Ha TY, Ha JW, Shin KY, Jeong YH et al (2006) Phosphorylation of amyloid precursor protein (APP) at Thr668 regulates the nuclear translocation of the APP intracellular domain and induces neurodegeneration. Mol Cell Biol 26:4327–4338. doi:10.1128/MCB.02393-05 PubMed

24.

Chen J, Zhou Y, Mueller-Steiner S, Chen LF, Kwon H, Yi S et al (2005) SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem 280:40364–40374. doi:10.1074/jbc.M509329200 PubMed

25.

Choi J, Sullards MC, Olzmann JA, Rees HD, Weintraub ST, Bostwick DE et al (2006) Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J Biol Chem 281:10816–10824. doi:10.1074/jbc.M509079200 PubMed

26.

Choi Y-C, Park GT, Kim T-S, Sunwoo IN, Steinert PM, Kim SY (2000) Sporadic inclusion body myositis correlates with increased expression and cross-linking by transglutaminases 1 and 2. J Biol Chem 275:8703–8710. doi:10.1074/jbc.275.12.8703 PubMed

27.

Cookson MR (2005) The biochemistry of Parkinson’s disease. Annu Rev Biochem 74:29–52. doi:10.1146/annurev.biochem.74.082803.133400 PubMed

28.

Cucciolla V, Borriello A, Oliva A, Galletti P, Zappia V, Ragione FD (2007) Reservatrol from basic science to the clinic. Cell Cycle 6:2495–2510PubMed

29.

Dalakas MC (2006) Inflammatory, immune, and viral aspects of inclusion-body myositis. Neurology 66:S33–S38. doi:10.1212/01.wnl.0000192129.65677.87 PubMed

30.

Dalakas MC (2006) Sporadic inclusion body myositis—diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol 2:437–447. doi:10.1038/ncpneuro0261 PubMed

31.

Dalakas MC (2008) Interplay between inflammation and degeneration: using inclusion body myositis to study “neruoinflammation”. Ann Neurol 64:1–3. doi:10.1002/ana.21452 PubMed

32.

Darin N, Kroksmark AK, Ahlander AC, Moslemi AR, Oldfors A, Tulinius M (2007) Inflammation and response to steroid treatment in limb-girdle muscular dystrophy 2. Eur J Paediatr Neurol 11:353–357. doi:10.1016/j.ejpn.2007.02.018 PubMed

33.

Derham BK, Harding JJ (1999) Alpha-crystallin as a molecular chaperone. Prog Retin Eye Res 18:463–509. doi:10.1016/S1350-9462(98)00030-5 PubMed

34.

Engel T, Goñi-Oliver P, Gomez de Barreda E, Lucas JJ, Hernandez F, Avila J (2008) Lithium, a potential protective drug in Alzheimer’s disease. Neurodegener Dis 5:247–249. doi:10.1159/000113715 PubMed

35.

Engel WK, Askanas V (2006) Inclusion-body myositis: clinical, diagnostic, and pathologic aspects. Neurology 66:S20–S29. doi:10.1212/01.wnl.0000192260.33106.bb PubMed

36.

Engel WK, Cunningham GG (1963) Rapid examination of muscle tissue – an improved trichrome method for fresh-frozen biopsy sections. Neurology 13:919–923PubMed

37.

Engel WK (1962) The essentiality of histo- and cytochemical studies of skeletal muscle in the investigation of neuromuscular disease. Neurology 12:778–794

38.

Engel WK (1971) “Ragged-red fibers” in ophthalmoplegia syndromes and their differential diagnosis. In: Abstracts of 2nd international congress on muscle diseases, Perth, Australia. Excerpta Med Inter Cong Series, vol 237, p 28

39.

Ferreira ST, Vieira MNN, De Felice FG (2007) Soluble protein oligomers as emerging toxins in Alzheimer’s and other amyloid diseases. IUBMB Life 59:332–345. doi:10.1080/15216540701283882 PubMed

40.

Forloni G, Terreni L, Bertani H, Fogliarino S, Ivernizzi R, Assini A et al (2002) Protein misfolding in Alzheimer’s and Parkinson’s disease: genetics and molecular mechanisms. Neurobiol Aging 23:957–976. doi:10.1016/S0197-4580(02)00076-3 PubMed

41.

Fratta P, Engel WK, McFerrin J, Davies KJA, Lin SW, Askanas V (2005) Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers. Am J Pathol 167:517–526PubMed

42.

Fratta P, Engel WK, van Leeuwen FW, Hol EM, Vattemi G, Askanas V (2004) Mutant ubiquitin UBB + 1 is accumulated in sporadic inclusion-body myositis muscle fibers. Neurology 63:1114–1117PubMed

43.

Glabe C (2001) Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer’s disease. J Mol Neurosci 17:137–145. doi:10.1385/JMN:17:2:137 PubMed

44.

Glabe C, Kayed R (2006) Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology 66:S74–S78. doi:10.1212/01.wnl.0000192103.24796.42 PubMed

45.

Haigis MC, Guarente LP (2006) Mammalian sirtuins—emerging roles in physiology, aging, and calorie restriction. Genes Dev 20:2913–2921. doi:10.1101/gad.1467506 PubMed

46.

Hashimoto M, Rockenstain E, Crews L, Masliah E (2003) Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer’s and Parkinson’s diseases. Neuromolecular Med 4:21–36. doi:10.1385/NMM:4:1-2:21 PubMed

47.

Hong WK, Han EH, Kim DG, Ahn JY, Park JS, Han BG (2007) Amyloid-beta-peptide reduces the expression level of mitochondrial cytochrome oxidase subunits. Neurochem Res 32:1483–1488. doi:10.1007/s11064-007-9336-7 PubMed

48.

Hoozemans JJM, van Haastert ES, Eikelenboom P, de Vos RAI, Rozemuller JM, Scheper W (2007) Activation of the unfolded protein response in Parkinson’s disease. Biochem Biophys Res Commun 354:707–711. doi:10.1016/j.bbrc.2007.01.043 PubMed

49.

Hussain I, Powell DJ, Howlett DR, Chapman GA, Gilmour L, Murdock PR et al (2000) ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase site. Mol Cell Neurosci 16:609–619. doi:10.1006/mcne.2000.0884 PubMed

50.

Imai Y, Soda M, Takahashi R (2000) Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem 275:35661–35664. doi:10.1074/jbc.C000447200 PubMed

51.

Jaworska-Wilczynska M, Wilczynski GM, Engel WK, Strickland DK, Weisgraber KH, Askanas V (2002) Three lipoprotein receptors and cholesterol in inclusion-body myositis muscle. Neurology 58:438–445PubMed

52.

Joulia-Ekaza D, Cabello G (2006) Myostatin regulation of muscle development: molecular basis, natural mutations, physiopathological aspects. Exp Cell Res 312:2401–2414. doi:10.1016/j.yexcr.2006.04.012 PubMed

53.

Keller JN, Hanni KB, Markesbery WR (2000) Impaired proteasome function in Alzheimer’s disease. J Neurochem 75:436–439. doi:10.1046/j.1471-4159.2000.0750436.x PubMed

54.

Kitazawa M, Trinh DN, LaFerla FM (2008) Inflammation induces tau pathology in inclusion-b0dy myositis model via glycogen syntase kinase-3β. Ann Neurol 64:15–24. doi:10.1002/ana.21325 PubMed

55.

Ksiezak-Reding H, Dickson DW, Davies P, Yen SH (1987) Recognition of tau epitopes by anti-neurofilament antibodies that bind to Alzheimer neurofibrillary tangles. Proc Natl Acad Sci USA 84:3410–3414. doi:10.1073/pnas.84.10.3410 PubMed

56.

Kudo T, Katayama T, Imaizumi K, Yasuda Y, Yatera M, Okochi M et al (2002) The unfolded protein response is involved in the pathology of Alzheimer’s disease. Ann N Y Acad Sci 977:349–355PubMed

57.

Kumamoto T, Ueyama H, Tsumura H, Toyoshima I, Tsuda T (2004) Expression of lysosome-related proteins and genes in the skeletal muscles of inclusion-body myositis. Acta Neuropathol 107:59–65. doi:10.1007/s00401-003-0774-2 PubMed

58.

LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid-beta in Alzheimer’s disease. Nat Rev Neurosci 8:499–509. doi:10.1038/nrn2168 PubMed

59.

Lee MS, Kao SC, Lemere CA, Xia W, Tseng HC, Zhou Y et al (2003) APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol 163:83–95. doi:10.1083/jcb.200301115 PubMed

60.

Lee IH, Cao L, Mostoslavsky R, Lombard DB, Liu J, Bruns NE et al (2008) A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc Natl Acad Sci USA 105:3374–3379. doi:10.1073/pnas.0712145105 PubMed

61.

Li H, Malhotra S, Kumar A (2008) Nuclear factor-kappa B signaling in skeletal muscle atrophy. J Mol Med 86:1113–1126. doi:10.1007/s00109-008-0373-8 PubMed

62.

Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J (2000) Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci USA 97:1456–1460. doi:10.1073/pnas.97.4.1456 PubMed

63.

Lindersson E, Beedholm R, Hojrup P, Moos T, Gai W, Hendil KB et al (2004) Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biochem 279:12924–12934

64.

Matus S, Lisbona F, Torres M, Leon C, Thielen P, Hetz C (2008) The stress rheostat: an interplay between the unfolded protein response (UPR) and autophagy in neurodegeneration. Curr Mol Med 8:157–172. doi:10.2174/156652408784221324 PubMed

65.

Michan S, Sinclair D (2007) Sirtuins in mammals: insights into their biological function. Biochem J 404:1–13. doi:10.1042/BJ20070140 PubMed

66.

Mirabella M, Alvarez RB, Bilak M, Engel WK, Askanas V (1996) Difference in expression of phosphorylated tau epitopes between sporadic inclusion-body myositis and hereditary inclusion-body myopathies. J Neuropathol Exp Neurol 55:774–786. doi:10.1097/00005072-199607000-00003 PubMed

67.

Morosetti R, Mirabella M, Gliubuzzi C, Broccolini A, De Angelis L, Tagliafico E (2007) MyoD expression restores defective myogenic differentiation of human mesoangioblasts from inclusion-body myositis muscle. Proc Natl Acad Sci USA 103:16995–17000. doi:10.1073/pnas.0603386103

68.

Moslemi AR, Lindberg C, Oldfors A (1997) Analysis of multiple mitochondrial DNA deletions in inclusion body myositis. Hum Mutat 10:381–386. doi:10.1002/(SICI)1098-1004(1997)10:5<381::AID-HUMU8>3.0.CO;2-IPubMed

69.

Needham M, Mastaglia FL (2007) Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 6:620–631. doi:10.1016/S1474-4422(07)70171-0 PubMed

70.

Nogalska A, D’Agostino C, Engel WK, Askanas V (2008) Reservatrol, a polyphenol found in red wine, reduces NFκB-activation and myostatin in endoplasmic-reticulum-stress (ERS)-provoked cultured human muscle fibers (CHMFs): relevance to treatment of sporadic inclusion-body myositis (s-IBM). Ann Neurol 64:S9

71.

Nogalska A, D’Agostino C, Engel WK, Davies KJ, Askanas V (2008) Decreased SIRT1 deacetylast activity in sporadic inclusion-body myositis. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2008.08.21

72.

Nogalska A, Engel WK, McFerrin J, Kokame K, Komano H, Askanas V (2006) Homocysteine-induced endoplasmic reticulum protein (Herp) is up-regulated in sporadic inclusion-body myositis and in endoplasmic reticulum stress-induced cultured human muscle fibers. J Neurochem 96:1491–1499. doi:10.1111/j.1471-4159.2006.03668.x PubMed

73.

Nogalska A, Wojcik S, Engel WK, McFerrin J, Askanas V (2007) Endoplasmic reticulum stress induces myostatin precursor protein and NF-kappaB in cultured human muscle fibers: relevance to inclusion body myositis. Exp Neurol 204:610–618. doi:10.1016/j.expneurol.2006.12.014 PubMed

74.

Olanow CW, McNaught KS (2006) Ubiquitin-proteasome system and Parkinson’s disease. Mov Disord 21:1806–1823. doi:10.1002/mds.21013 PubMed

75.

Oldfors A, Moslemi AR, Jonasson L, Ohlsson M, Kollberg G, Lindberg C (2006) Mitochondrial abnormalities in inclusion-body myositis. Neurology 66:S49–S55. doi:10.1212/01.wnl.0000192127.63013.8d PubMed

76.

Paciello O, Wojcik S, Engel WK, McFerrin J, Askanas V (2006) Parkin and its association with α-synuclein and AßPP in inclusion-body myositis and AßPP over-expressing cultured human muscle fibers. Acta Myol 25:13–22PubMed

77.

Prayson RA, Cohen ML (1997) Ubiquitin immunostaining and inclusion-body myositis: study of 30 patients with inclusion body myositis. Hum Pathol 28:887–892. doi:10.1016/S0046-8177(97)90002-2 PubMed

78.

Qin W, Yang T, Ho L, Zhao Z, Wang J, Chen L et al (2006) Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem 281:21745–21754. doi:10.1074/jbc.M602909200 PubMed

79.

Santorelli FM, Sciacco M, Tanji K, Shanske S, Vu TH, Golzi V et al (1996) Multiple mitochondrial DNA deletions in sporadic inclusion-body myositis: a study of 56 patients. Ann Neurol 39:789–795. doi:10.1002/ana.410390615 PubMed

80.

Sarkozi E, Askanas V, Johnson SA, McFerrin J, Engel WK (1994) Expression of β-amyloid precursor protein gene is developmentally regulated in human muscle fibers in vivo and in vitro. Exp Neurology 128:27–33

81.

Schlossmacher MG, Frosch MP, Gai WP, Medina M, Sharma N, Forno L et al (2002) Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol 160:1655–1667PubMed

82.

Schmidt J, Barthel K, Wrede A, Salajegheh M, Bahr M, Dalakas MC (2008) Interrelation of inflammatory and APP in sIBM: IL-1β induces accumulation of β-amyloid in skeletal muscle. Brain 131:1228–1240. doi:10.1093/brain/awn053 PubMed

83.

Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81:741–766PubMed

84.

Selkoe DJ (2003) Aging, amyloid, and Alzheimer’s disease: a perspective in honor of Carl Cotman. Neurochem Res 28:1705–1713. doi:10.1023/A:1026065122854 PubMed

85.

Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R et al (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson’s disease. Science 293:263–269. doi:10.1126/science.1060627 PubMed

86.

Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D et al (1999) Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402:537–540. doi:10.1038/990114 PubMed

87.

Sisodia S, St. George-Hyslop PH (2002) Gamma-secretase, Notch, Abeta, and Alzheimer’s disease: where do the presenilins fit in? Nat Rev Neurosci 3:281–290. doi:10.1038/nrn785 PubMed

88.

Stege GJ, Renkawek K, Overkamp PS, Verschuure P, van Rijk AF, Reijnen-Aalbers A et al (1999) The molecular chaperone alphaB-crystallin enhances amyloid beta neurotoxicity. Biochem Biophys Res Commun 262:152–156. doi:10.1006/bbrc.1999.1167 PubMed

89.

Suto R, Srivastava PK (1995) A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 269:1585–1588. doi:10.1126/science.7545313 PubMed

90.

Taira T, Saito YY, Niki T, Iguchi-Ariga SM, Takahashi K, Ariga H (2004) DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep 5:213–218. doi:10.1038/sj.embor.7400074 PubMed

91.

Terracciano C, Engel WK, Askanas V (2008) In sporadic inclusion-body myositis (s-IBM) muscle biopsies, cytochrome oxidase (COX) negative muscle fibers do not correlate with either inflammation or with aggregates containing amyloid-^β (A^β) or phosphorylated tau (p-tau). Neurology 70:A304. doi:10.1212/01.wnl.0000296829.66406.14

92.

Terracciano C, Nogalska A, Engel WK, Askanas V (2008) Lithium exerts a beneficial effect on amyloid-β precursor protein (AβPP)-overexpressing cultured human muscle fibers (CHMFs). Ann Neurol 64:S12

93.

Terracciano C, Nogalska A, Engel WK, Askanas V (2008) Novel demonstration of phosphorylated amyloid-β precursor protein (AßPP) in sporadic inclusion-body myositis (s-IBM) muscle fibers. Neurology 70:A304. doi:10.1212/01.wnl.0000296829.66406.14

94.

Terracciano C, Nogalska A, Engel WK, Wojcik S, Askanas V (2008) In inclusion-body myositis muscle fibers, Parkinson-associated DJ-1 is increased and oxidized. Free Radic Biol Med 45:773–779PubMedCrossRef

95.

Todd DJ, Lee AH, Glimcher LH (2008) The endoplasmic reticulum stress response in immunity and autoimmunity. Nat Rev Immunol 8:663–674. doi:10.1038/nri2359 PubMed

96.

Triantafilou M, Fradelizi D, Triantafilou K (2001) Major histocompatibility class one molecule associates with glucose regulated protein (GRP) 78 on the cell surface. Hum Immunol 62:764–770. doi:10.1016/S0198-8859(01)00269-5 PubMed

97.

Tsai YC, Fishman PS, Thakor NV, Oyler GA (2003) Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J Biol Chem 278:22044–22055. doi:10.1074/jbc.M212235200 PubMed

98.

Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, Mizuno H et al (2008) Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer’s and Parkinson’s diseases. PLoS One 3:e3135. doi:10.1371/journal.pone.0003135 PubMed

99.

van Leeuwen FW, Hol EM, Fischer DF (2006) Frameshift proteins in Alzheimer’s disease and in other conformational disorders: time for the ubiquitin-proteasome system. J Alzheimers Dis 9:319–325PubMed

100.

Vaquero A, Sternglanz R, Reinberg D (2007) NAD+-dependent deacetylation of H4 lysine 16 by class III HDACs. Oncogene 26:5505–5520. doi:10.1038/sj.onc.1210617 PubMed

101.

Vattemi G, Checler F, Engel WK, Askanas V (2003) Amyloid-β42 is preferentially deposited in muscle biopsies of patients with sporadic inclusion-body myositis (s-IBM). Neurology 60:333–334

102.

Vattemi G, Engel WK, McFerrin J, Askanas V (2003) Cystatin C colocalizes with amyloid-β and co-immunoprecipitates with amyloid-β precursor protein in sporadic inclusion-body myositis muscle. J Neurochem 85:1539–1546. doi:10.1046/j.1471-4159.2003.01798.x PubMed

103.

Vattemi G, Engel WK, McFerrin J, Askanas V (2004) Endoplasmic reticulum stress and unfolded protein response in inclusion-body myositis muscle. Am J Pathol 164:1–7PubMed

104.

Vattemi G, Engel WK, McFerrin J, Buxbaum JD, Pastorino L, Askanas V (2001) Presence of BACE1 and BACE2 in muscle fibres of patients with sporadic inclusion-body myositis. Lancet 358:1962–1964. doi:10.1016/S0140-6736(01)06969-0 PubMed

105.

Vattemi G, Engel WK, McFerrin J, Pastorino L, Buxbaum JD, Askanas V (2003) BACE1 and BACE2 in pathologic and normal human muscle. Exp Neurol 179:150–158PubMed

106.

Vattemi G, Kefi M, Engel WK, Askanas V (2003) Nicastrin, a novel protein participating in amyloid-β production, is overexpressed in sporadic inclusion-body myositis muscle. Neurology 60:A315

107.

Vetrivel KS, Thinakaran G (2006) Amyloidogenic processing of beta-amyloid precursor protein in intracellular compartments. Neurology 66:S69–S73. doi:10.1212/01.wnl.0000192107.17175.39 PubMed

108.

Voges D, Zwickl P, Baumeister W (1999) The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 68:1015–1068. doi:10.1146/annurev.biochem.68.1.1015 PubMed

109.

Walsh DM, Selkoe DJ (2007) A beta oligomers—a decade of discovery. J Neurochem 101:1172–1184. doi:10.1111/j.1471-4159.2006.04426.x PubMed

110.

Wang H-Q, Takahashi R (2006) Expanding insights on the involvement of endoplasmic reticulum stress in Parkinson’s disease. Antioxid Redox Signal 9:553–561. doi:10.1089/ars.2006.1524

111.

Wojcik S, Engel WK, McFerrin J, Askanas V (2005) Myostatin is increased and complexes with amyloid-beta within sporadic inclusion-body myositis muscle fibers. Acta Neuropathol 110:173–177. doi:10.1007/s00401-005-1035-3 PubMed

112.

Wojcik S, Engel WK, McFerrin J, Paciello O, Askanas V (2006) AbetaPP-oeverexpression and proteasome inhibition increase αB-crystallin in cultured human muscle: relevance to inclusion-body myositis. Neuromuscul Disord 16:839–844. doi:10.1016/j.nmd.2006.08.009 PubMed

113.

Wojcik S, Engel WK, Yan R, McFerrin J, Askanas V (2007) NOGO is increased and binds to BACE 1 in sporadic inclusion-body myositis and in AßPP-overexpressing cultured human muscle fibers. Acta Neuropathol 114:517–526. doi:10.1007/s00401-007-0281-y PubMed

114.

Wojcik S, Nogalska A, McFerrin J, Engel WK, Oledzka G, Askanas V (2007) Myostatin precursor protein is increased and associates with amyloid-beta precursor protein in inclusion-body myositis culture model. Neuropathol Appl Neurobiol 33:238–242. doi:10.1111/j.1365-2990.2006.00821.x PubMed

115.

Yamamoto H, Schoonjans K, Auwerx J (2007) Sirtuin functions in health and disease. Mol Endocrinol 21:1745–1755. doi:10.1210/me.2007-0079 PubMed

116.

Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA et al (2004) Modulation of NF-κappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23:2369–2380. doi:10.1038/sj.emboj.7600244 PubMed

117.

Sun Y, MacRae TH (2005) The small heat shock proteins and their role in human disease. FEBS J 272:2613–2627. doi:10.1111/j.1742-4658.2005.04708.x PubMed

118.

Zhang K, Kaufman RJ (2006) The unfolded protein response: a stress signaling pathway critical for health and disease. Neurology 66:S102–S109. doi:10.1212/01.wnl.0000192306.98198.ec PubMed

119.

Zhang K, Kaufman RJ (2008) From endoplasmic-reticulum stress to the inflammatory response. Nature 454:455–462. doi:10.1038/nature07203 PubMed

Title: Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer’s and Parkinson’s disease brains
Authors: Valerie Askanas
W. King Engel
Publication date: 01-12-2008
Publisher: Springer-Verlag
Published in: Acta Neuropathologica / Issue 6/2008
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-008-0449-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer’s and Parkinson’s disease brains

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2008

LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions

Transient intraneuronal Aβ rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice

How satisfied are authors with our service?

Subpial astrocytosis and focal leptomeningeal angiotropic astrocytosis leading to vascular compression: observations made in a case of mitochondrial encephalopathy

Enduring involvement of tau, β-amyloid, α-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism–dementia complex of Guam (ALS/PDC)

Kurt Jellinger Prize 2009 for Outstanding Scientific Writing in Neuropathology